Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03143374
Other study ID # 824867
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date September 2016
Est. completion date December 2025

Study information

Verified date February 2024
Source University of Pennsylvania
Contact Dahlia Kamel
Phone 215-662-6134
Email kamel.dahlia@pennmedicine.upenn.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).


Description:

The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells, including Alzheimer's disease, Parkinson's disease, Lewy body disease and Frontotemporal degeneration. 18F-AV-1451 (formally known as 18F-T807) is a specialized radioactive PET tracer that sticks to the tau protein in the brain. In this study, researchers will use 18F-AV-1451 to form images of tau binding in the brain. 18F-AV-1451 is an investigational or experimental imaging agent that has not yet been approved by the Food and Drug Administration for use in brain imaging. In this study, researchers want to find out how accurate and useful 18F-AV-1451 is in imaging patients who have problems with thinking, remembering, speech, and visual activities, and may be diagnosed with different types of neurodegenerative disease. This study will help test how imaging measures may provide information that could be used to determine diagnosis for patients in the future. The results of the PET/CT scan will be compared with other information obtained under related protocols, including brain magnetic resonance imaging (MRI), spinal fluid and cognitive test results.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 2025
Est. primary completion date September 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 100 Years
Eligibility INCLUSION CRITERIA FOR NEURODEGENERATIVE SUBJECTS 1. Participants has been diagnosed with one of the following neurodegenerative diseases: FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD- ALS 2. Participants will be 18 years of age or older 3. Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. If the subject is unable to provide informed consent, the subject's legal representative may consent on behalf of the patient, but the patient will be asked to confirm assent. 4. Participants must be willing and able to comply with scheduled visits and imaging procedures. 5. Subject is concurrently enrolled in centers UNICORN(842873) protocol. INCLUSION CRITERIA FOR HEALTHY CONTROL SUBJECTS 1. Participants will be 18 years of age or older. 2. Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. 3. Participants must be willing and able to comply with scheduled visits and imaging procedures. 4. Subject is concurrently enrolled in centers UNICORN(842873) protocol EXCLUSION CRITERIA FOR ALL SUBJECTS 1. Females who are pregnant or breast feeding at the time of the baseline PET/CT scan will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential at screening and within 24 hours of any scheduled PET/CT. 2. Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician 3. Any medical or psychological condition that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study 4. The investigators may choose to exclude participants with clinically significant cardiovascular disease and/or documented abnormalities on ECG out of an abundance of caution. 5. The investigators of UNICORN (IRB #842873) have determined the participant has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan. ADDITIONAL EXCLUSION CRITERIA FOR HEALTHY CONTROL SUBJECTS 1. Pre-existing psychiatric conditions (e.g., active depression, schizophrenia, or active anxiety) or neurological conditions (e.g., stroke, epilepsy, head trauma) per medical record review or self-report. 2. Current use of psychoactive medications or substances per medical record review or self-report.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
18F-AV-1451
The experimental tracer used for this study is called 18F-AV-1451 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain. Participants will undergo a baseline 18F-AV-1451 brain scan. If funding is available, participants will be asked to return for one or more longitudinal visits, including a 18F-AV-1451 brain scan, every 9 to 18 months after the prior visit. The 18F-AV-1451 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania.

Locations

Country Name City State
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
University of Pennsylvania Avid Radiopharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Regional uptake Examine regional anatomic distribution of PET-tau uptake comparatively in dementia syndromes and PET-Tau uptake with neuropsychology and MRI regional GM atrophy at baseline collected under other center protocols. Uptake with neuropsychology and MRI regional GM atrophy at baseline. 10 years
Secondary Changes over time Use regression to relate longitudinal neuropsychological and regional MRI decline in dementia syndromes to baseline regional PET-tau uptake. 10 years
Secondary CSF Correlate Correlate CSF total and phosphorylated (p-tau/t-tau) tau with regional PET-tau uptake in dementia syndromes at baseline. 10 years
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02402426 - Brain Health Registry: An Online Registry to Identify and Assess Subjects for Brain Research
Completed NCT00714636 - Cerebrospinal Fluid Repository N/A
Active, not recruiting NCT00907283 - Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA) Phase 2
Terminated NCT00718003 - Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS). N/A
Completed NCT00016562 - Cause and Pathogenesis of Neurometabolic Disorders N/A
Terminated NCT00718445 - Pennsylvania Consortium: Clinical Database N/A
Recruiting NCT02869048 - Amyotrophic Lateral Sclerosis and the Innate Immune System N/A
Completed NCT00718393 - Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS) N/A
Terminated NCT00718107 - Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology N/A
Completed NCT00001365 - Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System Phase 2
Recruiting NCT00271622 - The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
Completed NCT01758510 - Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis Phase 1
Terminated NCT00718016 - Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient N/A
Completed NCT00718497 - Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population N/A
Completed NCT00718458 - EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS) N/A
Completed NCT02418546 - Electronic-health Application To Measure Outcomes REmotely Clinical Trial N/A
Completed NCT00716131 - Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program N/A